Proton Tx Plus Chemo Seen Beneficial in NSCLC


“The use of proton beam radiotherapy and concurrent chemotherapy may improve clinical outcomes for patients with inoperable stage III non-small cell lung cancer (NSCLC), while reducing the toxic effects of treatment, researchers from MD Anderson Cancer Center have found.

“The researchers, led by Joe Y. Chang, MD, PhD, reported that the median overall survival of 26.5 months observed in their study ‘was encouraging, and in accord with our original statistical goal of 24 months.’ ”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.